Haniel becomes cornerstone investor in Gilde Healthcare V

Medical staff

German family-equity company Haniel has become a regional cornerstone investor of Gilde Investment Management's Gilde Healthcare V fund.

The growth capital fund focuses on healthcare sectors including digital health, medtech and therapeutics, both in Europe and North America. 

The fund will have a special focus on private healthcare companies enabling improved care at affordable cost, according to Haniel. Treatment and diagnosis of infectious diseases like Covid-19 forms part of its strategy.

Gilde Healthcare V raised EUR416 million and is supported by a mix of international investors. The fund will typically make equity investments in a portfolio company of between EUR10 to 40 million.

With its EUR30 million commitment Haniel is one of the largest investors in the fund. The company will participate in various strategic cooperation initiatives, and is taking the next step of its strategic repositioning to invest only in business models that contribute to “a future worth living”.

“This is a great opportunity for us to support high growth companies in the healthcare sector, where innovations to enable better healthcare outcomes at reduced costs are needed urgently,” said Thomas Schmidt, CEO of Haniel.

“Even in these difficult times, we stick to our principle of investing only in companies across the entire business life cycle that make a contribution to solving global challenges and contribute to a future worth living,” he added.

Haniel follows the UNs’ Sustainable Development Goals and economic megatrends. The key to this strategy is the restructuring of the portfolio, focusing on people, planet, and progress, according to the firm.

Going forward, Haniel is going to invest EUR500 million in companies in earlier stages of their development directly and through investment funds.